No Picture
News

Histogen Announces Closing of $3.5 Million Private Placement

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced today the closing of its previously announced private placement for the issuance and sale… Click here to view original post… […]

No Picture
News

NEUVOGEN Announces Appointment of Chief Financial Officer

SAN DIEGO: SAN DIEGO, Dec. 21, 2021 /PRNewswire/ — NEUVOGEN, an immunoncology company, is pleased to announce the appointment of George Montgomery as Chief Financial Officer. He will oversee corporate finance, partnership strategy, and capital markets relationships. "George is a highly respected biotechnology leader and brings a proven track record… Click here to view original post… […]

No Picture
News

Cytonus Therapeutics Announces Publication in Nature Biomedical Engineering of Preclinical Results to Support Disease-Specific Drug-Delivery Capabilities of their Novel Cargocyte™ Platform

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a US-based biotechnology company developing an innovative drug-delivery platform technology called Cargocytes, today announced the publication of a peer reviewed research paper in the high impact journal, Nature Biomedical Engineering. The study showed that Cargocytes, which are genetically engineered with a GPS-like cellular navigation system,… Click here to view original post… […]

No Picture
News

iXCells Biotechnologies Announces Strategic Initiatives to Drive Continued Growth

SAN DIEGO–(BUSINESS WIRE)–iXCells Biotechnologies (the “Company”), a provider of induced pluripotent stem cells (iPSCs), differentiation services, primary cells, media and reagents for drug discovery and development, today announced key growth initiatives. The Company is implementing a cloud-based ERP solution powered by Oracle NetSuite® that will integrate workflows and create operational… Click here to view original post… […]

No Picture
News

GB HealthWatch raises $3.5 million in pre-series C funding to expand genetic-based preventive health products and services for cardiometabolic diseases and Alzheimer’s

SAN DIEGO: SAN DIEGO, Dec. 21, 2021 /PRNewswire-PRWeb/ — GB HealthWatch, a genetic-based preventive health company, announced today it raised $3.5 million in pre-series C funding. The investors participating in the round are Trinity Power LLC, a series B investor, and the founder of GB HealthWatch. The company plans to… Click here to view original post… […]

No Picture
News

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

SAN DIEGO: SAN DIEGO, Dec. 21, 2021 /PRNewswire/ — BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the… Click here to view original post… […]

No Picture
News

SkylineDx raises new capital from Novalis LifeSciences and Van Herk Investments

ROTTERDAM, Netherlands and SAN DIEGO: ROTTERDAM, Netherlands and SAN DIEGO, Dec. 21, 2021 /PRNewswire/ — Today, SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux’ largest biotech investors Van Herk Investments, to further solidify its position in the USA… Click here to view original post… […]

No Picture
News

Dalrada Corporation Expands Presence in Top Three Growth Industries: Clean Energy, Healthcare, Technology (IT)

SAN DIEGO–(BUSINESS WIRE)—- $DFCO #CleanEnergy–Dalrada Corporation (OTCQB: DFCO, "Dalrada") would like to express its sincere appreciation for its investors, shareholders, staff and followers for their support throughout 2021. This calendar year marks a synchronous period in Dalrada’s history when its impactful innovations and solutions of all its subsidiaries expanded market… Click here to view original post… […]

No Picture
News

Thermo Fisher Scientific Updates TaqMan SARS-CoV-2 Mutation Panel to Enable Direct Identification of Omicron Variant

CARLSBAD, Calif.: CARLSBAD, Calif., Dec. 21, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to enable direct detection of the Omicron SARS-CoV-2 variant. The panel is designed with a customizable menu of real-PCR genotyping… Click here to view original post… […]

No Picture
News

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics

SAN DIEGO–(BUSINESS WIRE)–Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire Protein Metrics, Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the Company’s R&D value chain to widen the biopharmaceutical protein… Click here to view original post… […]

No Picture
News

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escalation Study of the Safety and Preliminary Efficacy of… Click here to view original post… […]

No Picture
Uncategorized

Mycrodose Therapeutics Operations Manager – Psychedelic Biotech/Pharma – Mycrodose Therapeutics – San Diego, CA

So a successful Operations Manager will need to: plan, organize, direct, manage, review and evaluate the activities, operations, programs and services provided… $60,000 – $85,000 a yearFrom Indeed – Mon, 20 Dec 2021 23:50:06 GMT […]

No Picture
News

Biocom California Purchasing Group Appoints Greg Giandomenico as Vice President and Managing Director

SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)–Biocom California Purchasing Group, the group purchasing organization serving California’s largest life science membership association, today announced the appointment of Greg Giandomenico as vice president and managing director. In this role, Giandomenico will oversee the strategy, contracts, sales and operations… Click here to view original post… […]

No Picture
News

AbbVie petitions trade commission to ban Alvotech’s Humira biosimilar; Cytokinetics licenses heart drug to Chinese partner

The AbbVie/Alvotech debacle on a Humira biosimilar has taken yet another turn — escalating tensions between the two biotechs. The pharma giant filed a complaint with the US International Trade Commission on Friday, trying to prevent Alvotech from selling a lower cost version of AbbVie’s Humira,… Click here to view original post… […]

No Picture
News

Tim Lu takes Senti and its gene circuit tech public in $296M deal riding on Omid Farokhzad’s SPAC

Omid Farokhzad Omid Farokhzad didn’t have to travel far to find a private biotech he wanted to take public with his $200 million blank-check company. Senti Bio — the synthetic biology play launched and now helmed by MIT whiz Tim Lu — will be merging… Click here to view original post… […]

No Picture
News

BIOATLA TO PRESENT AT 40th ANNUAL J.P. MORGAN VIRTUAL HEALTHCARE CONFERENCE

SAN DIEGO: SAN DIEGO, Dec. 20, 2021 /PRNewswire/ — BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present at… Click here to view original post… […]

No Picture
News

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

SAN DIEGO: SAN DIEGO, Dec. 20, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New… Click here to view original post… […]